Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHC Bausch Health Companies Inc

Closed Good Friday 04-17 16:00:00 EDT

5.10

+0.60

+13.33%

盘后5.24

+0.14+2.83%

19:55 EDT

High5.27	Low4.51	Vol9.21M
Open4.51	D1 Closing4.50	Amplitude16.78%
Mkt Cap1.88B	Tradable Cap1.41B	Total Shares369.51M
T/O46.62M	T/O Rate3.32%	Tradable Shares277.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BHC","market":"US","secType":"STK","nameCN":"Bausch Health Companies Inc","latestPrice":5.1,"timestamp":1744920000000,"preClose":4.5,"halted":0,"volume":9207125,"hourTrading":{"tag":"盘后","latestPrice":5.2443,"preClose":5.1,"latestTime":"19:55 EDT","volume":583144,"amount":2991130.04364,"timestamp":1744934152434},"delay":0,"floatShares":277392083,"shares":369512514,"eps":-0.125,"marketStatus":"Closed Good Friday","change":0.6,"latestTime":"04-17 16:00:00 EDT","open":4.51,"high":5.265,"low":4.51,"amount":46616330.3430125,"amplitude":0.167778,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":4.5,"preHourTrading":{"tag":"盘前","latestPrice":4.56,"preClose":4.5,"latestTime":"08:57 EDT","volume":10,"amount":45.599999999999994,"timestamp":1744894647434},"postHourTrading":{"tag":"盘后","latestPrice":5.2443,"preClose":5.1,"latestTime":"19:55 EDT","volume":583144,"amount":2991130.04364,"timestamp":1744934152434},"volumeRatio":3.1498673629972567,"impliedVol":0.885,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/BHC","defaultTab":"news","newsList":[{"id":"2528743778","title":"Bausch says court grants summary judgment in favor of FDA, Salix, and Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2528743778","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528743778?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 03:50","pubTimestamp":1744919412,"startTime":"0","endTime":"0","summary":"Bausch Health Companies (BHC) and its gastroenterology business, Salix Pharmaceuticals, announced the U.S. District Court for the District of Colum...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bausch-says-court-grants-summary-judgment-in-favor-of-fda-salix-and-teva?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bausch-says-court-grants-summary-judgment-in-favor-of-fda-salix-and-teva?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2528972002","title":"U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich","url":"https://stock-news.laohu8.com/highlight/detail?id=2528972002","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528972002?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 03:40","pubTimestamp":1744918800,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc.  , and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al. , denied Norwich's motion for a preliminary injunction treated as a motion for summary judgment in its lawsuit against the U.S. Food and Drug Administration .Norwich had asked the District Court for a judgment declaring the FDA's decision to issue tentative approval for Norwich's Abbreviated New Drug Application  for XIFAXAN  550 mg and failure to determine Teva Pharmaceuticals USA, Inc.  had forfeited its 180-day exclusivity were arbitrary, capricious, and contrary to law. Norwich sought an injunction directing the FDA to immediately grant Final Approval to Norwich's ANDA for XIFAXAN  550 mg. Norwich argued that if upheld, FDA's determination will prohibit Norwich from marketing those products until at least June","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-district-court-grants-summary-194000494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2526541236","title":"Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526541236","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526541236?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 04:15","pubTimestamp":1744316100,"startTime":"0","endTime":"0","summary":"Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025. LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program will award six exceptional students, impacted by dermatologic conditions, a scholarship of up to $10,000 in support of their higher education goals.\"It is our distinct honor to continue the ASPIRE HIGHER Scholarship Program to help support students affected by dermatologic conditions, and to recognize and thank the dedicated healthcare providers who treat them. We are truly inspired by our students' perseverance as they work to achieve their educational dreams,\" said Donald Pearl, Senior Vice President, Ortho Dermatologics, Bausch Health.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-announces-ortho-dermatologics-201500552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2526516760","title":"Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526516760","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526516760?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 21:05","pubTimestamp":1744290300,"startTime":"0","endTime":"0","summary":"Bausch + Lomb BLCO shares ended the last trading session 13.9% higher at $12.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 29.2% loss over the past four weeks.Bausch + Lomb stock surged amid a broader market rebound following the Trump administration’s announcement of a temporary halt on reciprocal tariffs for most countries. The market is also upbeat about the company’s surrounding its impending first-quarter 2025 financial results, which is slated to release on April 30 before the opening bell.This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $1.15 billion, up 4.4% from the year-ago quarter.Bausch + Lomb Corporation  : Free Stock Analysis Report. Charles River Laboratories International, Inc.  : Free Stock Analysis Report. This article originally published on Zac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-lomb-blco-moves-13-130500986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4198","LU0390134368.USD","CRL","BK4585","BK4530","BHC","BK4588","BLCO","BK4007"],"gpt_icon":0},{"id":"2526361954","title":"Bausch Health Unit Signs LoI for Public Listing of Acne Gel Cabtreo in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2526361954","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526361954?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 21:12","pubTimestamp":1744204341,"startTime":"0","endTime":"0","summary":"Bausch Health's  Canada unit said Wednesday that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for public drug plan coverage in Canada for its acne vulgaris treatment Cabtreo.The company said the agreement allows Bausch Health Canada to finalize the listing of Cabtreo under individual government drug plans across Canada, including federal, provincial and territorial programs.No financial terms of the agreement were disclosed.Cabtreo has been approved by Health Canada as a triple-combination topical acne treatment, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2526365587","title":"Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris","url":"https://stock-news.laohu8.com/highlight/detail?id=2526365587","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526365587?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:00","pubTimestamp":1744200000,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc.  today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance  for Canadian public drug plan coverage for PrCABTREOTM  gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1. The letter of intent means Bausch Health, Canada Inc. can now proceed to finalizing individual listing agreements for CABTREO to be covered by each of Canada's government drug plans, including those of all provinces and territories and the federal government . The letter of intent spells out the agreed terms of those listing agreements, given the participation of all Canadian public drug plans in the pCPA process.\"We are very pleased to have reached agreement with the pan-Canadian Pharmaceutical Alliance on the terms that will lead to the availability of CABTREO to Canadi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-canada-inc-pan-120000138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["03160","BK4099","TM","BHC","BK4585","BK4007","BK4588","BK4604","BK4555"],"gpt_icon":0},{"id":"2525078510","title":"Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2525078510","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525078510?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 02:51","pubTimestamp":1744051887,"startTime":"0","endTime":"0","summary":"Bausch Health  is expected to post Q1 revenue of $2.24 billion, shy of the $2.29 billion estimate of analysts polled by FactSet, RBC Capital Markets said in an earnings preview Monday.RBC analysts also said they expect the pharmaceutical company to report Q1 adjusted EBITDA of $720 million while analysts surveyed by FactSet expect $769.8 million.The investment firm said it revised its Q1 estimates due to foreign exchange movements and updated prescription data. Regarding tariffs, RBC analysts said they plan to seek updated comments from management on the potential impact to the company. Previously, Bausch Health's management said they were forecasting an impact of less than $500 million to cash flow under a 25% tariff rate.Bausch Health is due to report Q1 results after the close on April 30.RBC cut its price target to $8.50 from $9 and kept a sector perform rating on the stock.Price: 5.09, Change: -0.25, Percent Change: -4.60","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHC"],"gpt_icon":0},{"id":"2525045826","title":"RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2525045826","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525045826?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 21:17","pubTimestamp":1744031832,"startTime":"0","endTime":"0","summary":"RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHC","PT"],"gpt_icon":0},{"id":"2525790090","title":"Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2525790090","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525790090?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 17:02","pubTimestamp":1744016548,"startTime":"0","endTime":"0","summary":"Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb  and its peers.The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-earnings-roundup-bausch-lomb-090228658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NYSE","BLCO","BHC","INSP"],"gpt_icon":0},{"id":"2525060229","title":"Bausch Health Companies Inc : RBC Cuts Target Price to $8.5 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2525060229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525060229?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 16:20","pubTimestamp":1744014038,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2524578268","title":"Bausch + Lomb's Q1 Earnings Expected in Line With Forecasts, RBC says","url":"https://stock-news.laohu8.com/highlight/detail?id=2524578268","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524578268?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 22:37","pubTimestamp":1743777428,"startTime":"0","endTime":"0","summary":"Bausch + Lomb  is set to report its Q1 results on April 30, with revenue and earnings before interest, taxes, depreciation, and amortization expected in line with consensus, RBC said in a report Friday.Investors will be closely watching for updates on the company's dry-eye disease prescription drugs, Miebo and Xiidra, as well as the financial impact and timeline for resolving the recent voluntary recall of certain enVista intraocular lenses, RBC said.\"Regarding tariffs, management has previously noted that the company primarily manufactures products within their country of origin, suggesting that most of the impact from tariffs would pertain to raw materials. Consequently, they had expected any headwinds to be minimal,\" the report said.RBC notes that foreign exchange headwinds, which had previously been a significant concern, have \"moderated,\" and revised forecasts now estimate a $24 million impact in Q1 and $45 million for the full year, down from a previous estimate of $100 million, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-lomb-apos-q1-earnings-143708271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC"],"gpt_icon":0},{"id":"2523896966","title":"Why Bausch + Lomb (BLCO) Shares Are Plunging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2523896966","media":"StockStory","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523896966?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:20","pubTimestamp":1743182437,"startTime":"0","endTime":"0","summary":"Shares of eyecare company Bausch + Lomb  fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the \"voluntary recall\" of certain implantable eye lenses reported the previous day.The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Bausch + Lomb?Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generativ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-bausch-lomb-blco-shares-172037768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007","BLCO","BK4198"],"gpt_icon":0},{"id":"2522395325","title":"Why Bausch + Lomb (BLCO) Stock Is Nosediving","url":"https://stock-news.laohu8.com/highlight/detail?id=2522395325","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522395325?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 02:54","pubTimestamp":1743101698,"startTime":"0","endTime":"0","summary":"Shares of eyecare company Bausch + Lomb  fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was due to the reports of toxic anterior segment syndrome . The recall may raise short-term concerns regarding product safety and regulatory scrutiny. Though the company emphasized that the reported cases of TASS involved only an extremely small fraction of implanted lenses.The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Bausch + Lomb?Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft  to Alphabet , Coca-Cola  to Monster Beverage  could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-bausch-lomb-blco-stock-185458180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1301847155.USD","USJW.SI","LU0097036916.USD","LU0256863811.USD","LU0787776722.HKD","IE0009G5SDU7.USD","IE00B5949003.HKD","LU0234572021.USD","LU1642822529.SGD","LU2506952170.USD","IE0034235303.USD","LU0444971666.USD","LU1235295455.SGD","SGXZ51526630.SGD","IE00BHPRN162.USD","BHC","MNST","LU0276348264.USD","LU2413666426.HKD","BLCO","LU1032466523.USD","LU1699723380.USD","LU2092937221.SGD","SG9999014880.SGD","BK4579","LU2462157665.USD","LU0345770993.USD","LU1121112475.USD","LU1228905037.USD","LU2756315664.SGD","LU2360032135.SGD","LU0048584097.USD","LU0894485498.HKD","LU1623119135.USD","LU0965508806.USD","LU2092937148.SGD","LU1934455863.HKD","LU0784385170.HKD","LU1003077747.HKD","LU0061474705.USD","LU0348723411.USD","LU1712237335.SGD","LU2097344431.USD","LU0345770308.USD","IE0034235295.USD","LU1868836757.USD","LU1868836914.USD"],"gpt_icon":1},{"id":"2522365379","title":"Bausch Health to Announce First Quarter Results on April 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2522365379","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522365379?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"A replay of the conference call will be available on the investor relations website.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-announce-first-quarter-110000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2522417884","title":"Bausch Health Prices Upsized Private Offering of Senior Secured Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2522417884","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522417884?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:41","pubTimestamp":1742928082,"startTime":"0","endTime":"0","summary":"Bausch Health Companies  on Tuesday priced its previously announced offering of US$4.4 billion aggregate principal amount of 10% senior secured notes due 2032 through an indirect wholly owned subsidiary.The company said the offering was upsized from an initial offering size of $4 billion aggregate principal amount and is expected to close the offering on April 8.Bausch Health intends to use the proceeds from the offering and borrowings under the New Term Loan Facility to: repay in full and cancel its existing credit agreement; and redeem all of its 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 6.125% Senior Secured Notes due 2027, 5.750% Senior Secured Notes due 2027 and its indirect unit's 9.000% Senior Secured Notes due 2028; and pay related fees, premiums and expenses; and for general corporate purposes.Shares of the company were last seen udown 0.85% at $10.33 on the Toronto Stock Exchange.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-prices-upsized-private-184122147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2522814598","title":"Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2522814598","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522814598?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:00","pubTimestamp":1742925600,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc.   today announced that it has priced its previously announced offering  of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032  through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. , a company incorporated under the laws of British Columbia, Canada  that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes. The Offering was upsized from an initial offering size of $4.0 billion aggregate principal amount. The Offering is expected to close on April 8, 2025, subject to the satisfaction of customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-announces-pricing-upsized-180000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2522703907","title":"Discover 3 Top Growth Companies With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2522703907","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522703907?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 01:05","pubTimestamp":1742835933,"startTime":"0","endTime":"0","summary":"As the United States market experiences a rally with major indices like the S&P 500 and Nasdaq posting gains, investor sentiment is buoyed by reports of potential tariff reductions. In this environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company's operations and prospects.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 205 stocks from our Fast Growing US Companies With High Insider Ownership screener.AlTi Global is projected to achieve profitability in the next three years, with earnings expected to grow at 119.26% annually, surpassing market averages. Despite this growth potential, recent financials show a decline in revenue and continued net losses. The company has undergone executive changes with the appointment of Mike Harrington as CFO, bringing extensive financial services experience. While insider trading d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-3-top-growth-companies-170533972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861217088.USD","BK4007","TBBB","DFS","BK4135","BK4588","LU1861220207.SGD","LU2360107671.USD","BHC","LU0106831901.USD","ALTI","BK4196","LQDA","LU1668664300.SGD","LU1791807156.HKD","BK4585","BK4113","BK4166"],"gpt_icon":1},{"id":"2521687217","title":"Shareholders in Bausch Health Companies (NYSE:BHC) are in the red if they invested three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2521687217","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521687217?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:00","pubTimestamp":1742652039,"startTime":"0","endTime":"0","summary":"Investing in stocks inevitably means buying into some companies that perform poorly. But long term Bausch Health Companies Inc.  shareholders have had a particularly rough ride in the last three year. Regrettably, they have had to cope with a 69% drop in the share price over that period. And more recent buyers are having a tough time too, with a drop of 25% in the last year. On the other hand, we note it's up 10.0% in about a month.Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.Given that Bausch Health Companies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholders-bausch-health-companies-nyse-140039786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","NYSE","BK4007"],"gpt_icon":0},{"id":"2521254347","title":"Bausch Health Announces Conditional Redemption of Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2521254347","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521254347?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:15","pubTimestamp":1742588100,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc.   today announced that  it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027  and  1375209 B.C. Ltd., the Company's indirect wholly-owned subsidiary , has delivered a conditional notice of redemption for all of its outstanding 9.000% Senior Secured Notes due 2028 . Each of the redemptions is conditioned upon the closing of debt financing transactions satisfactory to the Company . The Company expects to satisfy this condition with its recently announced financing transaction, which includes  $4,000 million aggregate principal amount of new senior secured notes due 2032 and  $3,400 million in borrowings under a new 5.5-year senior secured term loan B facility.A copy of each conditional notice of redemption was issued to the record holders of eac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-announces-conditional-redemption-201500238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2521230752","title":"Bausch (BHC) Down 0.7% Since Last Earnings Report: Can It Rebound?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521230752","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521230752?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 23:30","pubTimestamp":1742571027,"startTime":"0","endTime":"0","summary":"It has been about a month since the last earnings report for Bausch Health . Shares have lost about 0.7% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.It turns out, estimates revision have trended upward during the past month.The consensus estimate has shifted 64.49% due to these changes.At this time, Bausch has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.Bausch Health Cos Inc.  : Fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-bhc-down-0-7-153027194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bauschhealth.com","stockEarnings":[{"period":"1week","weight":0.167},{"period":"1month","weight":-0.2725},{"period":"3month","weight":-0.3145},{"period":"6month","weight":-0.375},{"period":"1year","weight":-0.4111},{"period":"ytd","weight":-0.3672}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.0619},{"month":2,"riseRate":0.666667,"avgChangeRate":0.037099},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.066965},{"month":4,"riseRate":0.6,"avgChangeRate":-0.004763},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.013304},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.002565},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.009218},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.003486},{"month":9,"riseRate":0.571429,"avgChangeRate":0.022231},{"month":10,"riseRate":0.6,"avgChangeRate":-0.048396},{"month":11,"riseRate":0.6,"avgChangeRate":0.047657},{"month":12,"riseRate":0.666667,"avgChangeRate":0.040388}],"exchange":"NYSE","name":"Bausch Health Companies Inc","nameEN":"Bausch Health Companies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bausch Health Companies Inc(BHC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bausch Health Companies Inc,BHC,Bausch Health Companies Inc股票,Bausch Health Companies Inc股票老虎,Bausch Health Companies Inc股票老虎国际,Bausch Health Companies Inc行情,Bausch Health Companies Inc股票行情,Bausch Health Companies Inc股价,Bausch Health Companies Inc股市,Bausch Health Companies Inc股票价格,Bausch Health Companies Inc股票交易,Bausch Health Companies Inc股票购买,Bausch Health Companies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bausch Health Companies Inc(BHC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction